Skip to main content

Table 1 Characteristics of patients with Edwardsiella tarda bacteremia

From: Characteristics and prognosis of patients with Edwardsiella tarda bacteremia at a single institution, Japan, 2005–2022

Patient

Total n = 38 (%)

Survivors at 30 d, n = 32 (%)

Death within 30 d, n = 3 (%)

p value

Survivors at 90 d, n = 23 (%)

Death within 90 d, n = 8 (%)

p value

Age (median) [range]

77.5 (25–98)

76.5 (25–92)

83 (79–85)

0.111

75 (25–87)

79 (70–90)

0.13

Sex, no. of patients

 Male

22 (57.9)

19 (59.4)

2 (66.7)

1.00

13 (56.5)

6 (75.0)

0.433

 Female

16 (42.1)

13 (40.6)

1 (33.3)

10 (43.5)

2 (25.0)

Symptoms, no. of patients

 Fever (≥ 37.5 °C)

26 (68.4)

22 (68.8)

2 (66.7)

1.00

14 (60.9)

7 (87.5)

0.222

 Appetite loss

17 (44.7)

12 (37.5)

3 (100)

0.069

7 (30.4)

6 (75.0)

0.043

 Nausea/vomiting

6 (15.8)

6 (18.6)

0 (0)

1.00

4 (17.4)

0 (0)

0.55

 Proceeded diarrhea

1 (2.6)

1 (3.1)

0 (0)

1.00

0 (0)

1 (12.5)

0.258

 Sepsis

9 (23.7)

8 (25.0)

1 (33.3)

1.00

2 (8.7)

5 (62.5)

0.006

Underlying disease*

 Solid tumor

       

 Hepatobiliary or pancreatic cancer

12 (31.6)

9 (28.1)

2 (66.7)

0.227

5 (21.7)

5 (62.5)

0.074

 Gastrointestinal cancer

6 (15.8)

5 (15.6)

1 (33.3)

0.442

3 (13.0)

2 (25.0)

0.583

 Lung cancer

4 (10.5)

4 (12.5)

0 (0)

1.00

3 (13.0)

1 (12.5)

1.00

 Prostate cancer

2 (5.3)

2 (6.3)

0 (0)

1.00

2 (8.7)

0 (0)

1.00

 Laryngeal cancer

3 (7.9)

3 (9.4)

0 (0)

1.00

3 (13.0)

0 (0)

0.55

 Hematologic malignancy

1 (2.6)

1 (3.1)

0 (0)

1.00

1 (4.3)

0 (0)

1.00

 Receipt of anticancer chemotherapy

11 (28.9)

10 (31.2)

1 (33.3)

1.00

6 (26.1)

2 (25.0)

0.676

 Receiving palliative care

6 (15.8)

3 (9.4)

2 (66.7)

0.047

0 (0)

5 (62.5)

0.0003

 Metastatic tumor

6 (15.8)

5 (15.6)

1 (33.3)

0.442

2 (8.7)

4 (50.0)

0.026

 Bile duct stent or drainage tube placement

8 (21.1)

5 (15.6)

2 (66.7)

0.095

4 (17.4)

3 (37.5)

0.335

 Diabetes mellitus

10 (26.3)

10 (31.3)

0 (0)

0.542

8 (34.8)

2 (25.0)

1.00

 Hypertension

18 (47.4)

16 (50.0)

1 (33.3)

1.00

11 (47.8)

4 (50.0)

1.00

 Cardiovascular disease

4 (10.5)

3 (9.4)

0 (0)

1.00

3 (13.0)

0 (0)

0.55

 Gallstone

17 (44.7)

14 (43.8)

0 (0)

0.259

12 (52.2)

1 (12.5)

0.095

 Chronic liver disease**

4 (10.5)

4 (12.5)

0 (0)

1.00

3 (13.0)

0 (0)

0.55

 Chronic lung disease***

7 (18.4)

6 (18.6)

0 (0)

1.00

6 (26.1)

0 (0)

0.298

 Chronic kidney disease****

3 (7.9)

2 (6.3)

0 (0)

1.00

2 (8.7)

0 (0)

1.00

 Dementia

3 (7.9)

1 (3.1)

1 (33.3)

0.166

0 (0)

2 (25.0)

0.060

 Stroke

7 (18.4)

6 (18.6)

0 (0)

1.00

2 (8.7)

2 (25.0)

0.268

 Receipt of any immunosuppressant*****

2 (5.3)

2 (6.3)

0 (0)

1.00

2 (8.7)

0 (0)

1.00

 Connective tissue disease

1 (2.6)

1 (3.1)

0 (0)

1.00

1 (4.3)

0 (0)

1.00

 Charlson comorbidity index (median) (range)

5 (0–11)

5 (0–11)

7 (5–10)

0.189

5 (1–11)

8.5 (5–10)

0.002

Types of bacteremia

 Monomicrobial bacteremia

22 (57.9)

19 (59.4)

1 (33.3)

0.565

14 (60.9)

3 (37.5)

0.412

 Polymicrobial bacteremia

16 (42.1)

13 (40.6)

2 (66.7)

0.565

9 (39.1)

5 (62.5)

0.412

Source of bacteremia

 Hepatobiliary

       

 Cholangitis

21 (55.7)

17 (53.1)

2 (66.7)

1.00

11 (47.8)

5 (62.5)

0.685

 Cholecystitis

7 (18.4)

5 (15.6)

0 (0)

1.00

4 (17.4)

0 (0)

0.55

 Liver abscess

4 (10.5)

4 (12.5)

0 (0)

1.00

4 (17.4)

0 (0)

0.55

 Gynecologic

2 (5.2)

2 (5.7)

0

1.00

1 (4.3)

0 (0)

1.00

 Intraabdominal abscess

3 (7.9)

2 (5.7)

1 (33.3)

0.242

0 (0)

2 (25.0)

0.013

 Appendicitis

1 (2.6)

1 (3.1)

0 (0)

1.00

0 (0)

0 (0)

1.00

 Spontaneous bacterial peritonitis

1 (2.6)

1 (3.1)

0 (0)

1.00

0 (0)

0 (0)

0.258

 Febrile neutropenia

1 (2.6)

1 (3.1)

0 (0)

1.00

1 (4.3)

0 (0)

0.258

 Unknown

1 (2.6)

1 (3.1)

0 (0)

1.00

0 (0)

1 (12.5)

0.258

  1. *With duplicates
  2. **Defined as cirrhosis, hepatitis B virus, or hepatitis C virus infection
  3. ***Including chronic obstructive pulmonary disease, intestinal pneumonia
  4. ****Defined as a serum creatinine level ≥ 2.0 mg/dL
  5. *****Taking or administrating immunosuppressants or immunomodulators, such as prednisolone